Popular search terms:
Search Results
29 results found-
MonoFIX-VF
It does not consult your doctor or contain complete information Individuals with factor IX levels haemophilia treatment centre.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-cmi-300.pdf -
Biostate Data Sheet
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds1900.pdf -
Australian PI . tradename (active ingredient)
4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MonoFIX®-VF is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia B. MonoFIX®-VF is not indicated for the treatment of factor II, VII or X deficiencies because it does not contain therapeutic levels of these coagulation factors.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-pi-400.pdf -
Our Company | CSL Behring Australia
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
https://www.cslbehring.com.au/our-company -
News | CSL Behring Australia
Press and News Releases from CSL Behring Australia
https://www.cslbehring.com.au/news -
Australian PI . Biostate (FVIII / VWF)
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-pi-v2700.pdf -
Research and Development Capabilities | CSL Behring Australia
Our scientists are recognized for their contributions to developing breakthrough medicines that have the potential to help patients worldwide.
https://www.cslbehring.com.au/research-and-development/research-and-development-capabilities -
Summary of Health Consumer Organisation support For the period: 01 Jan 2019 - 31 Dec 2019 Company: CSL Behring
$25,000.00 The Haemophilia Foundation of Australia (HFA) is an organisation that represents people with haemophilia, von Willebrand disorder and other inherited bleeding disorders.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/transparency-reports/csl-behring-2019-health-consumer-organisation-support-pdf.pdf -
Biostate
Biostate® is also used in patients with haemophilia A, a bleeding •
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-cmi-v2500.pdf -
Newsroom
Press and News Releases from CSL Behring Australia
https://www.cslbehring.com.au/news/newsroom